Orchard Therapeutics wins Innovation Passport for OTL-201 in MPS-IIIA
Orchard Therapeutics, a subsidiary of Japan's Kyowa Kirin, has been awarded an Innovation Passport designation for OTL-201, its investigational haemopoietic stem cell (HSC) gene therapy for mucopolysaccharidosis type IIIA (MPS-IIIA), under the UK's Innovative Licensing and Access Pathway (ILAP). The designation, announced on 30 April 2026, marks OTL-201 as one of only three therapies to receive the accolade under the pathway's refreshed iteration, which launched in January 2025.
MPS-IIIA, or Sanfilippo syndrome type A, is a rare and invariably fatal neurometabolic condition arising from mutations in both copies of the SGSH gene. The resulting enzyme deficiency allows heparan sulfate to accumulate to toxic levels throughout the body, including the central nervous system, driving progressive loss of cognitive and motor function. The condition affects roughly one in 100,000 live births, and median life expectancy is estimated at around 14.5 years. No approved disease-modifying therapy currently exists.
What OTL-201 involves
OTL-201 is an ex vivo autologous therapy: a patient's own blood stem cells are harvested, a functional copy of the SGSH gene is inserted using a modified viral vector, and the corrected cells are reinfused with the aim of addressing the underlying enzymatic defect in a single treatment. The candidate is currently being evaluated in an investigator-sponsored proof-of-concept trial in the UK (NCT04201405). It already holds rare paediatric disease and orphan drug designations from the FDA and orphan designation from the EMA, giving it a meaningful suite of regulatory incentives across major markets.
Andrew Olaye, general manager for UK and Ireland at Orchard Therapeutics, said the Innovation Passport designation was "further validation that the life-changing value OTL-201 has the potential to provide children with MPS-IIIA and their families."
ILAP and the regulatory read-across
The ILAP was first introduced in January 2021 and substantially overhauled for its January 2025 relaunch. Its central proposition — described by the MHRA as the only end-to-end access pathway in the world with multi-stakeholder engagement established from early clinical development — brings together the MHRA, NICE, the Scottish Medicines Consortium, the All Wales Therapeutics and Toxicology Centre, and the NHS into a single collaborative framework. For developers of rare-disease therapies, where small trial populations make conventional evidence generation challenging, that kind of early payer and HTA engagement can meaningfully compress the gap between regulatory approval and reimbursement.
The MPS-IIIA gene therapy space remains sparsely populated. Several academic groups and smaller biotechs have explored enzyme replacement and gene therapy approaches for Sanfilippo syndrome subtypes, but none has reached the market. Orchard's own commercial trajectory bears close watching: the company voluntarily withdrew its approved gene therapy Strimvelis from the EU market in 2022 amid manufacturing and commercial challenges, and its broader portfolio has been restructured under Kyowa Kirin's stewardship since the 2023 acquisition. The ILAP pathway offers Orchard an opportunity to build early relationships with NHS decision-makers — a critical consideration given the NHS's historically cautious approach to one-time, high-cost gene therapies.
Near-term milestones for OTL-201 will centre on data from the ongoing proof-of-concept trial, which will need to demonstrate durable SGSH enzyme reconstitution and, ultimately, neurological stabilisation to support a pivotal programme. The Innovation Passport is an entry point, not an approval signal, and Orchard has not indicated a timeline for pivotal trial initiation.